Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies

Journal of Clinical Investigation

Volumn 127, Issue 10, 2017, Pages 3657-3674

  Cole, Christopher B ^a,c   Russler Germain, David A ^a   Ketkar, Shamika ^a   Verdoni, Angela M ^a,c   Smith, Amanda M ^a   Bangert, Celia V ^a,d   Helton, Nichole M ^a   Guo, Mindy ^a   Klco, Jeffery M ^b   O'Laughlin, Shelly ^a   Fronick, Catrina ^a   Fulton, Robert ^a   Chang, Gue Su ^a   Petti, Allegra A ^a   Miller, Christopher A ^a   Ley, Timothy J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; RAS PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; PROTEIN P21;

ACUTE MYELOID LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW CELL; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; DIMERIZATION; DNA METHYLATION; DNMT3A GENE; DOWN REGULATION; GENE; GENE MUTATION; HAPLOINSUFFICIENCY; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; ANIMAL; CELL LINE; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEMATOPOIETIC STEM CELL; MALE; MAPK SIGNALING; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; CELL LINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, MUTANT STRAINS; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85030549771     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI93041     Document Type: Conference Paper

References (56)

1. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
2. Walter MJ, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158.
3. Roller A, et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia. 2013;27(7):1573-1578.
4. Yan XJ, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-315.
5. Hou HA, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119(2):559-568.
6. Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
7. Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP. DNMT3A R882 mutations predict a poor prognosis in AML: a meta-analysis from 4474 patients. Medicine (Baltimore). 2016;95(18):e3519.
8. Klco JM, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811-822.
9. Shlush LI, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328-333.
10. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-1478.
11. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
12. Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
13. Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem. 2012;287(37):30941-30951.
14. Russler-Germain DA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442-454.
15. Spencer DH, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168(5):801-816.e13.
16. Cancer Genome Atlas Research Network, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
17. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-257.
18. Holz-Schietinger C, Matje DM, Harrison MF, Reich NO. Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J Biol Chem. 2011;286(48):41479-41488.
19. Bielefeld-Sevigny M. AlphaLISA immunoassay platform-the "no-wash" high-throughput alternative to ELISA. Assay Drug Dev Technol. 2009;7(1):90-92.
20. Purdy MM, Holz-Schietinger C, Reich NO. Identification of a second DNA binding site in human DNA methyltransferase 3A by substrate inhibition and domain deletion. Arch Biochem Biophys. 2010;498(1):13-22.
21. Aoki A, et al. Enzymatic properties of de novotype mouse DNA (cytosine-5) methyltransferases. Nucleic Acids Res. 2001;29(17):3506-3512.
22. Suetake I, Miyazaki J, Murakami C, Takeshima H, Tajima S. Distinct enzymatic properties of recombinant mouse DNA methyltransferases Dnmt3a and Dnmt3b. J Biochem. 2003;133(6):737-744.
23. Cole CB, et al. PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest. 2016;126(1):85-98.
24. Kogan SC, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245.
25. Poitras JL, et al. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model. Oncotarget. 2016;7(43):69124-69135.
26. Walter MJ, et al. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc Natl Acad Sci U S A. 2005;102(35):12513-12518.
27. Mayle A, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125(4):629-638.
28. Chang YI, et al. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia. 2015;29(9):1847-1856.
29. Jeong M, et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014;46(1):17-23.
30. Shen Y, et al. A map of the cis-regulatory sequences in the mouse genome. Nature. 2012;488(7409):116-120.
31. Zheng GX, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.
32. de Graaf CA, et al. Haemopedia: An Expression Atlas of Murine Hematopoietic Cells. Stem Cell Reports. 2016;7(3):571-582.
33. Challen GA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23-31.
34. Frith CH, Highman B, Burger G, Sheldon WD. Spontaneous lesions in virgin and retired breeder BALB/c and C57BL/6 mice. Lab Anim Sci. 1983;33(3):273-286.
35. Frith CH. Incidence of hepatic metastases for various neoplasms in several strains of mice. Toxicol Pathol. 1983;11(2):120-128.
36. Ward JM, Mahler JF, Maronpot RR. In: Sundberg JP, Frederickson RM, eds. Pathology of genetically engineered mice. Ames, IA: Iowa State University Press; 2000.
37. Celik H, et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood. 2015;125(4):619-628.
38. Meyer SE, et al. DNMT3A haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia. Cancer Discov. 2016;6(5):501-515.
39. Haney SL, et al. Promoter hypomethylation and expression is conserved in mouse chronic lymphocytic leukemia induced by decreased or inactivated Dnmt3a. Cell Rep. 2016;15(6):1190-1201.
40. Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H. de novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med. 2007;204(4):715-722.
41. Landau DA, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-530.
42. Puente XS, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519-524.
43. Guryanova OA, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22(12):1488-1495.
44. Xi Y, Li W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinformatics. 2009;10:232.
45. Jühling F, Kretzmer H, Bernhart SH, Otto C, Stadler PF, Hoffmann S. metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data. Genome Res. 2016;26(2):256-262.
46. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome Biol. 2012;13(10):R83.
47. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Cornell University Library. https://arxiv.org/abs/1303.3997. Accessed August 28, 2017.
48. Li H. The sequence alignment/mapformat and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
49. Larson DE, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311-317.
50. Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
51. Saunders CT, et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28(14):1811-1817.
52. McKenna A, et al. The genome analysis toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
53. Ye K, et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertsions from paired-end short reads. Bioinformatics. 2009;25(21):2865-2871.
54. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5(4):557-572.
55. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-193.
56. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.